FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976005722> ?p ?o ?g. }

• W1976005722 endingPage "1073" @default.
• W1976005722 startingPage "1072" @default.
• W1976005722 abstract "Reoperative heart valve replacement for degenerated xenografts is associated with an increased surgical risk. We used our experience with transcatheter transapical aortic valve implantation to perform a transapical off-pump aortic valve-in-a-valve implantation. Hemodynamic function was excellent and the patient had a fast and uneventful recovery. Reoperative heart valve replacement for degenerated xenografts is associated with an increased surgical risk. We used our experience with transcatheter transapical aortic valve implantation to perform a transapical off-pump aortic valve-in-a-valve implantation. Hemodynamic function was excellent and the patient had a fast and uneventful recovery. Dr Dehdashtian discloses that he has a financial relationship with Edwards Lifesciences. Dr Dehdashtian discloses that he has a financial relationship with Edwards Lifesciences. Heart valve replacement is a routinely performed in elderly patients using third-generation xenografts, with modern anticalcification treatment providing good hemodynamic function and sufficient longevity [1Schoen F.J. Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention.Ann Thorac Surg. 2005; 79: 1072-1080Abstract Full Text Full Text PDF PubMed Scopus (535) Google Scholar]. However, xenograft degeneration with subsequent repeat stenosis or incompetence requiring reoperation may occur. Reoperation is technically feasible in most patients, but the risk may be increased. Relatively few studies are published on such patients, but most quote a mortality risk for valve reoperation between 6% and 15% [2Jamieson W.R.E. Burr L.H. Miyagishima R.T. et al.Reoperation for bioprosthetic aortic structural failure - risk assessment.Eur J Cardiothorac Surg. 2003; 24: 873Crossref PubMed Scopus (89) Google Scholar, 3Eitz T. Fritzsche D. Kleikamp G. Zittermann A. Horstkotte D. Körfer R. Reoperation of the aortic valve in octogenarians.Ann Thorac Surg. 2006; 82: 1385-1391Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar]. Transcatheter heart valve implantation has been recently introduced into clinical practice using transfemoral and transapical approaches [4Grube E. Schuler G. Buellesfeld L. et al.Percutaneous aortic valve replacement for severe aortic stenosis in high risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.J Am Coll Cardiol. 2007; 50: 69-76Abstract Full Text Full Text PDF PubMed Scopus (875) Google Scholar, 5Webb J.G. Chandavimol M. Thompson C.R. et al.Percutanous aortic valve implantation retrograde from the femoral artery.Circulation. 2006; 113: 842-850Crossref PubMed Scopus (787) Google Scholar, 6Walther T. Falk V. Borger M.A. et al.Minimally invasive transapical beating heart aortic valve implantation—proof of concept.Eur J Cardiothorac Surg. 2007; 31: 9-15Crossref PubMed Scopus (205) Google Scholar]. On the basis of this experience together with experimental testing demonstrating excellent results for valve-in-a-valve (VinV) implantation [7Walther T. Falk V. Dewey T. et al.Valve-in-a-valve concept for transcatheter minimally invasive redo xenograft implantation.J Am Coll Cardiol. 2007; 50: 56-60Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar] we were able to successfully perform VinV implantation. In March 2007, an 82-year-old woman presented with symptomatic (New York Heart Association Functional Class III) aortic xenograft stenosis 9 years after receiving a 21-mm Perimount prosthesis (Edwards Lifesciences, Irvine, CA). Echocardiography revealed severe aortic stenosis with a maximum flow velocity of 4.5 m/s, a valve opening area of 0.8 cm2, and severely restricted cusp motion. Because of her significantly increased perioperative risk, with a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) predicted risk for death of 21%, and the Society Thoracic Surgeons risk assessment of 9.2%, she was considered for transapical minimally invasive off-pump VinV implantation. The patient gave informed consent for a protocol that has been approved by our local Ethics Board. Valve size selection for VinV implantation was based on specific bench testing. The VinV implantation was performed in a hybrid operative theatre. Femoral arterial and venous wires were inserted percutaneously, and an arterial sheath was placed. This would allow for immediate femoral cannulation and initiation of cardiopulmonary bypass, if required. A pigtail catheter was introduced through the arterial sheath into the aortic root for angiographic visualization. After an anterolateral minithoracotomy in the fifth intercostal space and vertical pericardiotomy, two purse-string sutures were placed in the apex of the left ventricle. The Seldinger technique was used to insert a 14F sheath antegrade across the stenosed xenograft. A superstiff guidewire was then introduced across the aortic arch into the descending aorta. Balloon dilatation of the stenosed xenograft was performed during a brief episode of rapid ventricular pacing (RVP) at 150 beats/min. A 33F transapical sheath and a cuffed Cribier Edwards transcatheter valve (Edwards Lifesciences) were subsequently inserted. The valve was positioned with the lower edge approximately 2 mm below the circular metal band of the stenosed xenograft (Fig 1). The VinV implantation was performed by inflating the balloon during a second episode of RVP (Fig 2). Good VinV position with full stent expansion and a slightly concave stent configuration at the inflow and outflow aspect was obtained (Fig 3). The guidewire and sheath were retrieved, and the left ventricular apex and the minithoracotomy were closed.Fig 2Valve-in-a-valve dilatation.View Large Image Figure ViewerDownload (PPT)Fig 3Final result shows a 23-mmn Edwards SAPIEN Transcatheter Heart Valve (THV) within a 21-mm Edwards Perimount conventional xenograft (Edwards Lifesciences, Irvine, CA). Aortic root angiogram confirms excellent valve-in-a-valve position, without incompetence, and patent coronary arteries.View Large Image Figure ViewerDownload (PPT) Hemodynamic function was stable throughout the procedure. Excellent valve function was confirmed by echocardiography and angiography, with no incompetence and low gradients (maximum velocity, 2.1 m/s). The patient had an uneventful recovery and was discharged in good health on postoperative day 11. The patient is doing well at home without any symptoms and with good valve function at 3 months of follow-up. Reoperative heart valve replacement may be associated with an increased surgical risk [2Jamieson W.R.E. Burr L.H. Miyagishima R.T. et al.Reoperation for bioprosthetic aortic structural failure - risk assessment.Eur J Cardiothorac Surg. 2003; 24: 873Crossref PubMed Scopus (89) Google Scholar, 3Eitz T. Fritzsche D. Kleikamp G. Zittermann A. Horstkotte D. Körfer R. Reoperation of the aortic valve in octogenarians.Ann Thorac Surg. 2006; 82: 1385-1391Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar]. Recently, transcatheter minimally invasive aortic valve implantation, using the transfemoral or the transapical approach, has been successfully performed in high-risk patients with native aortic valve stenosis [4Grube E. Schuler G. Buellesfeld L. et al.Percutaneous aortic valve replacement for severe aortic stenosis in high risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.J Am Coll Cardiol. 2007; 50: 69-76Abstract Full Text Full Text PDF PubMed Scopus (875) Google Scholar, 5Webb J.G. Chandavimol M. Thompson C.R. et al.Percutanous aortic valve implantation retrograde from the femoral artery.Circulation. 2006; 113: 842-850Crossref PubMed Scopus (787) Google Scholar, 6Walther T. Falk V. Borger M.A. et al.Minimally invasive transapical beating heart aortic valve implantation—proof of concept.Eur J Cardiothorac Surg. 2007; 31: 9-15Crossref PubMed Scopus (205) Google Scholar]. The VinV implantation is a logical further step. Experimental VinV testing [7Walther T. Falk V. Dewey T. et al.Valve-in-a-valve concept for transcatheter minimally invasive redo xenograft implantation.J Am Coll Cardiol. 2007; 50: 56-60Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar], laboratory analysis on the ideal valve size to be implanted into the degenerated xenograft and clinical experience with transapical aortic valve implantation in patients with native aortic valve disease were important prerequisites for successful clinical application of the VinV concept. Valve-in-a-valve implantation is an intriguing concept for minimally invasive reoperative heart valve replacement in the presence of degenerated xenografts, especially in high-risk elderly patients. The minimally invasive approach and the good hemodynamic outcome led to a fast and uneventful recovery in our patient. It is possible that such minimally invasive VinV re-replacement procedures may lead to more frequent use of xenografts during initial heart valve procedures or a lowering of the recommended age for bioprosthetic implantation in the future. Future consideration of VinV procedures in patients with failing bioprosthetic valves should take into account the different failure modes of porcine vs pericardial xenografts. Whereas bovine pericardium tends to have progressive stiffening that leads to stenosis, porcine cusps tend to develop severe calcification that may potentially lead to a higher risk of embolization during VinV implantation. We believe that minimally invasive beating heart off-pump VinV implantation offers a valuable therapeutic option for future patients, especially for those at high surgical risk." @default.
• W1976005722 created "2016-06-24" @default.
• W1976005722 creator A5007095434 @default.
• W1976005722 creator A5015390174 @default.
• W1976005722 creator A5021842628 @default.
• W1976005722 creator A5033250422 @default.
• W1976005722 creator A5042925324 @default.
• W1976005722 creator A5045219045 @default.
• W1976005722 creator A5057178455 @default.
• W1976005722 creator A5086702927 @default.
• W1976005722 creator A5088924700 @default.
• W1976005722 date "2008-03-01" @default.
• W1976005722 modified "2023-10-03" @default.
• W1976005722 title "Human Minimally Invasive Off-Pump Valve-in-a-Valve Implantation" @default.
• W1976005722 cites W163579839 @default.
• W1976005722 cites W1971410641 @default.
• W1976005722 cites W2001785066 @default.
• W1976005722 cites W2119621273 @default.
• W1976005722 cites W2145872362 @default.
• W1976005722 cites W2148154533 @default.
• W1976005722 cites W2156922522 @default.
• W1976005722 doi "https://doi.org/10.1016/j.athoracsur.2007.12.040" @default.
• W1976005722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18291201" @default.
• W1976005722 hasPublicationYear "2008" @default.
• W1976005722 type Work @default.
• W1976005722 sameAs 1976005722 @default.
• W1976005722 citedByCount "109" @default.
• W1976005722 countsByYear W19760057222012 @default.
• W1976005722 countsByYear W19760057222013 @default.
• W1976005722 countsByYear W19760057222014 @default.
• W1976005722 countsByYear W19760057222015 @default.
• W1976005722 countsByYear W19760057222016 @default.
• W1976005722 countsByYear W19760057222017 @default.
• W1976005722 countsByYear W19760057222018 @default.
• W1976005722 countsByYear W19760057222019 @default.
• W1976005722 countsByYear W19760057222020 @default.
• W1976005722 countsByYear W19760057222021 @default.
• W1976005722 countsByYear W19760057222022 @default.
• W1976005722 countsByYear W19760057222023 @default.
• W1976005722 crossrefType "journal-article" @default.
• W1976005722 hasAuthorship W1976005722A5007095434 @default.
• W1976005722 hasAuthorship W1976005722A5015390174 @default.
• W1976005722 hasAuthorship W1976005722A5021842628 @default.
• W1976005722 hasAuthorship W1976005722A5033250422 @default.
• W1976005722 hasAuthorship W1976005722A5042925324 @default.
• W1976005722 hasAuthorship W1976005722A5045219045 @default.
• W1976005722 hasAuthorship W1976005722A5057178455 @default.
• W1976005722 hasAuthorship W1976005722A5086702927 @default.
• W1976005722 hasAuthorship W1976005722A5088924700 @default.
• W1976005722 hasBestOaLocation W19760057221 @default.
• W1976005722 hasConcept C126322002 @default.
• W1976005722 hasConcept C141071460 @default.
• W1976005722 hasConcept C164705383 @default.
• W1976005722 hasConcept C2780714102 @default.
• W1976005722 hasConcept C71924100 @default.
• W1976005722 hasConceptScore W1976005722C126322002 @default.
• W1976005722 hasConceptScore W1976005722C141071460 @default.
• W1976005722 hasConceptScore W1976005722C164705383 @default.
• W1976005722 hasConceptScore W1976005722C2780714102 @default.
• W1976005722 hasConceptScore W1976005722C71924100 @default.
• W1976005722 hasIssue "3" @default.
• W1976005722 hasLocation W19760057221 @default.
• W1976005722 hasLocation W19760057222 @default.
• W1976005722 hasOpenAccess W1976005722 @default.
• W1976005722 hasPrimaryLocation W19760057221 @default.
• W1976005722 hasRelatedWork W1586374228 @default.
• W1976005722 hasRelatedWork W2003938723 @default.
• W1976005722 hasRelatedWork W2047967234 @default.
• W1976005722 hasRelatedWork W2089201504 @default.
• W1976005722 hasRelatedWork W2118496982 @default.
• W1976005722 hasRelatedWork W2364998975 @default.
• W1976005722 hasRelatedWork W2369162477 @default.
• W1976005722 hasRelatedWork W2439875401 @default.
• W1976005722 hasRelatedWork W4238867864 @default.
• W1976005722 hasRelatedWork W2525756941 @default.
• W1976005722 hasVolume "85" @default.
• W1976005722 isParatext "false" @default.
• W1976005722 isRetracted "false" @default.
• W1976005722 magId "1976005722" @default.
• W1976005722 workType "article" @default.